Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.49 |
| ▸ | TDO2 | P48775 | 6/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11322151 | 0.85 | IDO1 (0.65) | IDO1TDO2CYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL11862661 | 0.84 | IDO1 (0.50) | IDO1TDO2CYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL11864697 | 0.83 | IDO1 (0.41) | IDO1TDO2CYP2C19SLC6A4SLC6A3 | |
| SCHEMBL11870346 | 0.79 | APLNR (0.39) | IDO1TDO2 | |
| SCHEMBL792136 | 0.77 | IDO1 (0.58) | IDO1TDO2CYP2C19SLC6A4SLC6A3 | |
| SCHEMBL21831232 | 0.74 | IDO1 (0.38) | IDO1TDO2CYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL11862016 | 0.73 | CYP11B1 (0.39) | IDO1TDO2ALDH1A1AOC3CYP2C9 | |
| SCHEMBL30986699 | 0.73 | CYP11B1 (0.39) | IDO1TDO2ALDH1A1AOC3CYP2C9 | |
| SCHEMBL30910920 | 0.73 | CYP11B1 (0.39) | IDO1TDO2ALDH1A1AOC3CYP2C9 | |
| SCHEMBL1928305 | 0.70 | IDO1 (0.69) | IDO1TDO2CYP2C19CYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739307-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | The General Hospital Corporation (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025010291-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | THE GENERAL HOSPITAL CORPORATION (US) | 2025-01-09 | — | — | WO | disclosed |